Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC
- Development stage
- Phase 1
- Lead developer
- PrimeVax
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
PV-001-DC is a cell-based cancer vaccine composed of autologous, monocyte-derived dendritic cells (mDCs) that are pulsed with tumor cell lysate containing tumor-associated antigens. This approach aims to stimulate the immune system by presenting these antigens to T cells, thereby inducing an anti-tumor immune response. The therapy is being developed primarily for advanced melanoma and is administered intravenously in clinical trials. The mechanism involves immunostimulatory and antineoplastic activities through activation of cytotoxic T lymphocytes and helper T cells via antigen presentation by mature dendritic cells[1][3][4][8]. PrimeVax Immuno-Oncology is the primary developer.
- Other names
- autologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC
Beyond the preview
Go deeper on Autologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC.